2000;284(10):1263-1270 Hamza RT, Hamed AI, Sallam MT
Oral semaglutide in type 2 diabetes
Its mechanism of action mimics the naturally occurring hormone GLP-1, regulating hunger and food intake, thereby promoting a feeling of fullness and reducing appetite
Semaglutide seems to have a slight edge in reducing the risk of side effects, based on studies that assessed the risk of GI upset and pancreatitis.2 10 In our conversations with diabetic GLP-1 RA users, weve found that doctors will often start patients out on Ozempic, which uses the same active ingredient as Wegovy (semaglutide), as opposed to a drug based on tirzepatide
Clinical Trial Results: Tirzepatide (All Forms Mounjaro, Zepbound, Compounded): Because the active ingredient is identical, effectiveness is the same: SURMOUNT-1 Trial Results (72 weeks): 15 mg dose: 22.5% average body weight loss 10 mg dose: 21.4% average body weight loss 5 mg dose: 15.0% average body weight loss 96% of patients lost at least 5% of body weight 89% of patients lost at least 10% of body weight 63% of patients lost at least 20% of body weight Real-World Effectiveness: Compounded tirzepatide produces identical results to brand-name because its the same molecule at the same doses
For instance, atrasentan, an ERA, reduced kidney outcome risk by 35% but was also associated with a non-significant increase in hospitalization for HF [16]